Ovid Therapeutics (OVID) Operating Expenses (2016 - 2026)

Ovid Therapeutics has reported Operating Expenses for 11 years, with the latest figure at $17.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 40.74% year-over-year to $17.8 million; the trailing twelve-month figure through Mar 2026 stood at $54.9 million (down 4.7% YoY), and the FY2025 full-year result was $49.7 million, down 20.43% from the prior year.
• Operating Expenses for Q1 2026 stood at $17.8 million, up from $13.0 million in the prior quarter.
• The five-year high for Operating Expenses was $20.7 million in Q2 2024, with the low at $10.8 million in Q4 2024.
• Historically, Operating Expenses has averaged $14.5 million across 5 years, with a median of $13.4 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses plunged 53.63% — and 2023, when it surged 50.01%.
• Ovid Therapeutics' Operating Expenses stood at $12.2 million in 2022, then surged by 50.01% to $18.3 million in 2023, then sank by 41.09% to $10.8 million in 2024, then rose by 20.49% to $13.0 million in 2025, then soared by 37.16% to $17.8 million in 2026.
• The last three Operating Expenses figures came in at $17.8 million (Q1 2026), $13.0 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.